The contraceptive drugs and devices market is witnessing steady growth, fueled by rising awareness of sexual wellness, government initiatives on family planning, and the increasing prevalence of sexually transmitted diseases and unintended pregnancies. With a projected CAGR of 5.93% through 2034, the market is advancing through new product launches, expanding accessibility, and the integration of AI-driven contraceptive solutions
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Contraceptive Drugs and Devices Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Contraceptive Drugs and Devices Market Revenue and Volume, By Product
8.1.1 Contraceptive Drugs
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Contraceptive Devices
8.1.2.1. Market Revenue and Volume Forecast
9.1. Contraceptive Drugs and Devices Market Revenue and Volume, By Distribution Channels Outlook
9.1.1. Hospital Pharmacy
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Retail Pharmacy
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Clinics
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Online Channels
9.1.4.1. Market Revenue and Volume Forecast
9.1.5. Public Channels & NGOs
9.1.5.1. Market Revenue and Volume Forecast
9.1.6. Other
9.1.6.1. Market Revenue and Volume Forecast
10.1. North America
10.1.1. Market Revenue and Volume Forecast, By Product
10.1.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, By Product
10.1.3.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, By Product
10.1.4.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, By Product
10.2.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, By Product
10.2.3.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, By Product
10.2.4.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, By Product
10.2.5.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, By Product
10.2.6.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, By Product
10.3.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, By Product
10.3.3.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, By Product
10.3.4.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, By Product
10.3.5.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, By Product
10.3.6.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, By Product
10.4.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, By Product
10.4.3.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, By Product
10.4.4.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, By Product
10.4.5.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, By Product
10.4.6.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, By Product
10.5.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, By Product
10.5.3.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, By Product
10.5.4.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook
11.1. Abbvie, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Afaxys, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Agile Therapeutics
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Bayer AG
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. China Resources (Holdings) Co., Ltd.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Church & Dwight Co., Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Cupid Limited
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Helm AG
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Johnson & Johnson Services, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Organon Group of Companies
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description